GRAIL, Inc. (GRAL): Cash & Equivalents
$249.73M
As of 2025-12-31
$55.65M
As of 2026-06-30
+1.1%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $249.73M | +16.6% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $214.23M | +120.2% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $97.29M | -59.7% | 2026-03-12, Balance as of period end |
| 2023-01-01, Fiscal 2022 | $241.60M | n/a | 2025-03-05, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| GRAIL, Inc. (GRAL) | 2025-12-31 | $249.73M | +16.6% |
| Biodesix Inc (BDSX) | 2025-12-31 | $18.99M | -27.7% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $495.98M | +159.0% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $124.25M | +35.9% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $50.19M | -9.0% |
| Exagen Inc. (XGN) | 2025-12-31 | $32.22M | +46.2% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $116.73M | -2.5% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $65.43M | -43.0% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $362.58M | +51.7% |
Compare GRAL, BDSX, BLLN, PSNL side by side · Screen every company in Services-Medical Laboratories ↗